Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J9CF
|
|||
| Former ID |
DPR000061
|
|||
| Drug Name |
IDDBCP-150101
|
|||
| Indication | Obesity [ICD-11: 5B81; ICD-10: E66] | Preclinical | [1] | |
| Sexual dysfunction [ICD-11: HA00-HA01] | Preclinical | [1] | ||
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocortin receptor 4 (MC4R) | Target Info | Agonist | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pathway Interaction Database | Syndecan-3-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.